74 results
8-K
EX-99.2
NTRA
Natera Inc
28 Feb 24
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
4:11pm
response assessment, which is recommended but difficult with current tools Validated in 283 patients (1024 time points) from the ISPY - 2 trial, showing
8-K
EX-99.2
NTRA
Natera Inc
9 Jan 24
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
7:07am
kidney, heart and lung transplant centers ordered Prospera commercially Transplant Chronic Kidney Disease Donor cfDNA assessment to detect active
424B5
5jtygvcubukn98 w4
7 Sep 23
Prospectus supplement for primary offering
4:12pm
S-3ASR
suj dfp5m
6 Sep 23
Automatic shelf registration
4:23pm
8-K
EX-99.2
19fcx l8d
9 May 23
Natera Reports First Quarter 2023 Financial Results
4:01pm
POSASR
wkwcqrcfp1nlq 5gy
6 Dec 22
Automatic shelf registration (post-effective amendment)
4:06pm
424B5
h4e23tcw3fm961hk l4j
16 Nov 22
Prospectus supplement for primary offering
4:59pm
S-3ASR
v02fhu cb
15 Nov 22
Automatic shelf registration
4:16pm
8-K
EX-99.2
cn0wpy6w5evig
4 Aug 22
Natera Reports Second Quarter 2022 Financial Results
4:13pm
8-K
EX-99.2
v1vfwz 5wnq8l0uku
5 May 22
Natera Reports First Quarter 2022 Financial Results
12:00am